Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002228
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of T-20 in HIV-Positive Adults
Sponsor:
Trimeris
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase II Evaluation of the Safety Plasma Pharmacokinetics and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection
Status:
COMPLETED
Status Verified Date:
1999-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults T-20 is an anti-HIV drug
Detailed Description:
Patients are randomly placed into 1 of 6 groups 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection The entire study lasts 7 weeks including a 2-week screening period followed by 28 days of treatment and 1 week of follow-up
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| TRI-003 | None | None | None |